Sernova Corp. Announces Appointment of New Chief Executive Officer
Sernova Corp. (TSX:SVA) (OTCQB:SEOVF), a clinical-stage biotech company focusing on regenerative medicine cell therapies, has appointed Jonathan Rigby as its new CEO. Rigby, a type 1 diabetic himself, brings extensive experience in raising capital, leading biotech companies to Nasdaq listings, and achieving strategic acquisitions. The Board believes Rigby's leadership will position Sernova to achieve its strategic milestones.
Rigby's background includes several CEO roles and board positions in biotech companies, particularly in the diabetes field. He holds a degree in biological sciences and an MBA. The appointment aims to drive Sernova's growth and realize its full potential in developing treatments for chronic diseases, including its ongoing phase 1/2a clinical trial in type 1 diabetes.
Sernova Corp. (TSX:SVA) (OTCQB:SEOVF), un'azienda biotecnologica in fase clinica che si concentra sulle terapie cellulari nella medicina rigenerativa, ha nominato Jonathan Rigby come nuovo CEO. Rigby, lui stesso diabetico di tipo 1, porta con sé una vasta esperienza nella raccolta di capitali, nella guida di aziende biotec a listino Nasdaq e nel conseguimento di acquisizioni strategiche. Il Consiglio crede che la leadership di Rigby posizionerà Sernova per raggiungere i suoi traguardi strategici.
Il background di Rigby include diversi ruoli di CEO e posizioni nel consiglio di amministrazione in aziende biotecnologiche, in particolare nel settore del diabete. Ha conseguito una laurea in scienze biologiche e un MBA. La nomina mira a guidare la crescita di Sernova e a realizzarne il pieno potenziale nello sviluppo di trattamenti per malattie croniche, compreso il suo attuale studio clinico di fase 1/2a sul diabete di tipo 1.
Sernova Corp. (TSX:SVA) (OTCQB:SEOVF), una compañía biotecnológica en etapa clínica centrada en terapias celulares de medicina regenerativa, ha designado a Jonathan Rigby como su nuevo CEO. Rigby, quien es diabético tipo 1, aporta una amplia experiencia en la captación de capital, en dirigir empresas biotecnológicas hacia listados en Nasdaq y en lograr adquisiciones estratégicas. La Junta cree que el liderazgo de Rigby posicionará a Sernova para alcanzar sus hitos estratégicos.
La trayectoria de Rigby incluye varios roles como CEO y posiciones en juntas directivas en empresas biotecnológicas, particularmente en el campo de la diabetes. Tiene un título en ciencias biológicas y un MBA. La designación tiene como objetivo impulsar el crecimiento de Sernova y realizar su pleno potencial en el desarrollo de tratamientos para enfermedades crónicas, incluyendo su ensayo clínico en fase 1/2a en diabetes tipo 1.
Sernova Corp. (TSX:SVA) (OTCQB:SEOVF)는 재생 의학 세포 치료에 중점을 둔 임상 단계의 생명공학 회사로, Jonathan Rigby를 새로운 CEO로 임명했습니다. Rigby는 1형 당뇨병 환자로 자본 조달, 생명공학 기업을 Nasdaq에 상장시키고 전략적 인수 성과를 거둔 풍부한 경험을 가지고 있습니다. 이사회는 Rigby의 리더십이 Sernova를 전략적 이정표를 달성하는 데 잘 위치시킬 것이라고 믿고 있습니다.
Rigby의 배경은 특히 당뇨병 분야에서 여러 생명공학 회사의 CEO 역할과 이사회 직위를 포함합니다. 그는 생물학적 과학 학위를 보유하고 있으며 MBA를 취득했습니다. 이번 임명은 Sernova의 성장 촉진과 만성 질병에 대한 치료 개발에서 최대 잠재력을 실현하기 위한 것으로, 현재 1형 당뇨병에 대한 1/2a 단계의 임상 시험을 진행하고 있습니다.
Sernova Corp. (TSX:SVA) (OTCQB:SEOVF), une entreprise biopharmaceutique en phase clinique spécialisée dans les thérapies cellulaires en médecine régénérative, a nommé Jonathan Rigby comme nouveau PDG. Rigby, lui-même diabétique de type 1, apporte une vaste expérience dans le financement, la direction d'entreprises biopharmaceutiques vers des cotations sur le Nasdaq et la réalisation d'acquisitions stratégiques. Le Conseil estime que le leadership de Rigby positionnera Sernova pour atteindre ses objectifs stratégiques.
Le parcours de Rigby comprend plusieurs rôles de PDG et des postes au conseil d'administration au sein d'entreprises biopharmaceutiques, notamment dans le domaine du diabète. Il est titulaire d'un diplôme en sciences biologiques et d'un MBA. La nomination vise à stimuler la croissance de Sernova et à réaliser son plein potentiel dans le développement de traitements pour les maladies chroniques, y compris son essai clinique en phase 1/2a sur le diabète de type 1.
Sernova Corp. (TSX:SVA) (OTCQB:SEOVF), ein biopharmazeutisches Unternehmen in klinischer Phase, das sich auf regenerative Zelltherapien konzentriert, hat Jonathan Rigby zu seinem neuen CEO ernannt. Rigby, selbst Typ-1-Diabetiker, bringt umfangreiche Erfahrung in der Kapitalaufnahme, der Führung von Biotech-Unternehmen zu Nasdaq-Notierungen und in der Umsetzung strategischer Akquisitionen mit. Der Vorstand ist der Ansicht, dass Rigbys Führung Sernova in die Lage versetzen wird, seine strategischen Meilensteine zu erreichen.
Rigbys Hintergrund umfasst mehrere CEO-Rollen und Aufsichtsratspositionen in Biotech-Unternehmen, insbesondere im Bereich Diabetes. Er hat einen Abschluss in biologischen Wissenschaften und einen MBA. Die Ernennung zielt darauf ab, das Wachstum von Sernova voranzutreiben und das volle Potenzial bei der Entwicklung von Behandlungen für chronische Krankheiten, einschließlich der laufenden klinischen Phase 1/2a-Studie bei Typ-1-Diabetes, zu realisieren.
- Appointment of experienced CEO with track record in biotech leadership
- New CEO has personal connection to company's mission as a type 1 diabetic
- CEO's experience in raising equity capital and achieving strategic acquisitions
- New leadership expected to drive achievement of strategic milestones
- None.
LONDON, Ontario and BOSTON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- August 12, 2024. Sernova Corp. (“Sernova” or the “Company”) (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage biotechnology company focused on the development of regenerative medicine cell therapies for treatment of chronic diseases, led by an ongoing phase 1/2a clinical trial in type 1 diabetes, is pleased to announce Mr. Jonathan Rigby as the Company’s new Chief Executive Officer.
James Parsons, on behalf of the Board of Directors of Sernova, stated, “The Board believes that Sernova is now positioned to achieve its strategic milestones under Jonathan’s leadership. Jonathan brings a track record of success raising equity capital for biotech companies. Jonathan has led multiple biotech companies through listings onto Nasdaq, and the achievement of key operational and clinical developments, leading to strategic acquisitions that have generated significant value for shareholders.”
On his appointment, Mr. Rigby commented, “As a type 1 diabetic myself, I am honored to serve the company and its shareholders as Sernova’s new CEO. I am passionate about Sernova’s mission and determined to lead the Company to realize its full potential. I have financed and grown multiple companies through to exits and my goal is clear; I will work tirelessly with the team to do the same for Sernova and its shareholders.”
Mr. Rigby has held several CEO roles and currently serves on the board of directors of cancer therapy company, Oncolytics Biotech Inc. (Nasdaq: ONCY), and IM Therapeutics, working in the diabetes field. He was formerly a board member of Xeris Pharmaceuticals, which developed and commercialized a product to treat type 1 diabetes severe hypoglycemia. Mr. Rigby holds a degree in biological sciences from the University of Sheffield, U.K., and has a master of business administration degree from the University of Portsmouth, U.K.
The Board thanks Ms. Cynthia Pussinen, the Company’s former CEO, for her dedication and service to the Company and wishes her the very best in her future endeavors.
ABOUT SERNOVA CORP.
Sernova Corp. is a clinical-stage biotechnology company that is developing therapeutic cell technologies that are implanted in patients inside its Cell Pouch™ System for chronic diseases, including an ongoing phase 1/2a trial in insulin-dependent diabetes and plans to enter the clinic in thyroid disease, and blood disorders that include hemophilia A. Sernova is currently focused on developing a ‘functional cure’ for insulin-dependent diabetes with its lead asset, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. On implantation, the Cell Pouch forms a natural vascularized tissue environment in the body for long-term survival and function of therapeutic cells that release essential factors that are absent or deficient in the bodies of patients with certain chronic diseases. Sernova’s Cell Pouch System has demonstrated its potential to be a ‘functional cure’ for people with T1D in an ongoing Phase 1/2 clinical study at the University of Chicago. In May 2022, Sernova and Evotec entered into a global strategic partnership to develop an implantable iPSC (induced pluripotent stem cells) based Cell Pouch islet replacement therapy. This partnership provides Sernova a potentially unlimited supply of insulin-producing cells to treat millions of patients with insulin-dependent diabetes (type 1 and type 2). Sernova continues to evaluate the potential for additional development programs that utilize its Cell Pouch System: a cell therapy for hypothyroid disease resulting from thyroid gland removal and an ex vivo lentiviral Factor VIII gene therapy for hemophilia A.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Christopher Barnes
VP, Investor Relations
Sernova Corp.
christopher.barnes@sernova.com
519-902-7923
www.sernova.com
FORWARD-LOOKING INFORMATION
This release contains statements that, to the extent they are not recitations of historical facts, may constitute “forward-looking statements” that involve various risks, uncertainties, and assumptions, including, without limitation, statements regarding the prospects, plans, and objectives of the company. Wherever possible, but not always, words such as "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential for" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur are used to identify forward-looking statements. These statements reflect management’s beliefs with respect to future events and are based on information currently available to management on the date such statements were made. Many factors could cause Sernova’s actual results, performances or achievements to not be as anticipated, estimated or intended or to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors could include, but are not limited to, the company’s ability to secure additional financing and licensing arrangements on reasonable terms, or at all; ability to conduct all required preclinical and clinical studies for the company’s Cell Pouch System and or related technologies, including the timing and results of those trials; ability to obtain all necessary regulatory approvals, or on a timely basis; ability to in-license additional complementary technologies; ability to execute its business strategy and successfully compete in the market; and the inherent risks associated with the development of biotechnology combination products generally. Many of the factors are beyond our control, including those caused by, related to, or impacted by the novel coronavirus pandemic. Investors should consult the company’s quarterly and annual filings available on www.sedarplus.ca for additional information on risks and uncertainties relating to the forward-looking statements. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
FAQ
Who is the new CEO of Sernova Corp (SEOVF)?
What is Jonathan Rigby's background in relation to Sernova's (SEOVF) focus?
What are the key strengths Jonathan Rigby brings to Sernova Corp (SEOVF)?
What is Sernova Corp's (SEOVF) current focus in clinical trials?
